CN103893353A - Traditional Chinese medicinal composition for bringing down fever and relieving pain and application thereof - Google Patents
Traditional Chinese medicinal composition for bringing down fever and relieving pain and application thereof Download PDFInfo
- Publication number
- CN103893353A CN103893353A CN201410150098.9A CN201410150098A CN103893353A CN 103893353 A CN103893353 A CN 103893353A CN 201410150098 A CN201410150098 A CN 201410150098A CN 103893353 A CN103893353 A CN 103893353A
- Authority
- CN
- China
- Prior art keywords
- herba
- fever
- bringing down
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicinal composition for bringing down fever and relieving pain and application thereof. The traditional Chinese medicinal composition contains a therapeutically effective ingredient and a pharmaceutically acceptable carrier, wherein the therapeutically effective ingredient is prepared from the following components in parts by weight: 1-3 parts of glabrous sarcandra herb, 1-2 parts of houttuynia cordata and 1-2 parts of carpet bugle. Pharmacological experiments prove that the traditional Chinese medicinal composition has functions of resisting bacteria, resisting inflammation, bringing down fever and relieving pain, and has a synergic bacteriostatic action when being combined with amoxicillin; in clinical, the composition can be used for preparing medicines for treating mild and moderate infectious diseases and serve as an auxiliary medicine for biotic; the traditional Chinese medicinal composition disclosed by the invention is expected to solve adverse reactions caused by excessive use of the biotic and prevent or delay generation of drug resistant strains.
Description
Technical field
The present invention relates to a kind of light, the infectious disease medicine of moderate or Chinese medicine composition of antibiotic adjuvant drug and uses thereof of can be used as.
Background technology
By various light, the grade and moderate infection disease due to pathogen, comprise as pharyngitis, tonsillitis, sinusitis, otitis media, periodontitis, acute bronchitis, acute episode of chronic bronchitis, pneumonia, skin soft-tissue infection, pure urinary tract infection (cystitis) and complexity urinary tract infection, acute pyelonephritis and rectum infection etc., be feel disease, frequently-occurring disease clinically, brought misery to patient's life.Clinically various light, grade and moderate infection diseases are mainly adopted to antibiotic therapy, correctly use antibiotic conventionally can obtain good curative effect.Deliver " antibacterial action of opinion penicillium culture " paper from Fu Laiming nineteen twenty-nine and count, the operation of antibiotic and human diseases has been gone through 80 years.But, due to antibiotic whole people's formula abuse, " superbacteria " that impels antibacterial to be evolved into have strong drug resistance ability, doctor almost to feel simply helpless to it, the result of abuse of antibiotics is the cost that we have to give one's life for.At present, the staphylococcus aureus with strong drug resistance ability at the separation rate of nosocomial infection up to more than 60%, taking tuberculosis as example, the tuberculosis that was once once close to disappearance because of antibiotic sterilization power has been staged a comeback, the whole world newly-increased 1,000 ten thousand cases of tuberculosis nearly every year at present, approximately there are every year 3000000 people to die from tuberculosis, the tuberculosis pathogenic bacteria majority of separating from these patients is the what is called " superbacteria " with strong drug resistance ability, and we have got back to again the antibiotic-free epoch seemingly.
Therefore, how to reduce antibiotic using dosage, frequency of utilization, become the urgent problem in light, grade and moderate infection disease therapeutic process.Chinese medicine have the not available safety of antibiotic, low toxicity, effectively, unique features that drug resistance is low, provide useful solution for solving abuse of antibiotics problem, practitioner starts to consider that coordinating antibiotic to use by Chinese medicine compound treats light, grade and moderate infection disease.
Herba Sarcandrae is Chloranthaceae plant plait Corallium Japonicum Kishinouye Sarcandra glabra(Thunb.) the dry Herb of Nakai, there is effect of anti-inflammation, dispelling wind and removing obstruction in the collateral, blood circulation promoting and dispersing pathogen accumulation.For pneumonia, appendicitis, cellulitis, rheumatic arthralgia, injury from falling down, tumor etc.
Herba Houttuyniae, is the dry aerial parts of Saururaceae herbaceos perennial Herba Houttuyniae, originates in each province on the south China Yangtze river basin, is China's conventional medical herbs among the people, can, at summer, fall flowering Sheng phase harvesting aerial parts, choose roguing grass, and using fresh herb or dry, with all herbal medicine.There is heat-clearing and toxic substances removing, effect of inducing diuresis to remove edema.Cure mainly pneumonia, lung abscess, hematodiarrhoea, malaria, edema, gonorrhea, leucorrhea, carbuncle, hemorrhoid, proctoptosis, eczema, tinea alba, scabies etc.
Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.), the herb of Labiatae bugle Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) Ajuga decumbens Thunb..Originate in the U.S..Main product Jiangsu, Anhui, Zhejiang, Shanghai, Sichuan, Fujian, Hubei, Hunan, Guangdong, Guangxi, Guizhou, Yunnan.Spring, summer, Qiu Junke gather, and dry or using fresh herb.There is heat-clearing and toxic substances removing, the effect of removing heat from blood suppressing the hyperactive liver.For upper respiratory tract infection, tonsillitis, pharyngitis, bronchitis, pneumonia etc.
On the other hand, in the various inflammation for the treatment of, also often there is the symptom of pain, heating for patient, therefore, often need to take the medicine of spasmolytic and cooling of relieving the pain, and the medicine of this class often has suitable side effect simultaneously, and be unfavorable for patient's recovery.
Summary of the invention
The object of the present invention is to provide the one analgesia Chinese medicine composition of bringing down a fever.
Another object of the present invention is to provide a kind of purposes of the above-mentioned analgesia Chinese medicine composition of bringing down a fever.
In order to reach above-mentioned purpose, solution of the present invention is:
The one analgesia Chinese medicine composition of bringing down a fever, comprises treatment active ingredient and the carrier that pharmaceutically can use, and described treatment active ingredient is made by the component of following weight proportion: 1～5 part of 1～5 part of Herba Sarcandrae, 1～5 part of Herba Houttuyniae and Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.).
Although among the people and clinically, above-mentioned three kinds of Chinese medicines all can be separately or compound recipe be used for the treatment of various inflammation, above-mentioned three kinds of Chinese medicines are share, performance advantage effect each other, is used for the treatment of various light, grade and moderate infection diseases, also belongs to first.Moreover, use the combining of above-mentioned three kinds of Chinese medicines have bring down a fever, analgesic effect, using in this Chinese medicine composition treats, without the extra medicine that uses relieve the pain spasmolytic and cooling.
In the embodiment of recommending, described treatment active ingredient is used following mode to make:
A, the Herba Houttuyniae of getting above-mentioned weight proportion, Herba Sarcandrae and Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.), water or 30-95% ethanol extraction, filter;
B, be directly concentrated into clear paste;
C, dry directly make.
In the embodiment of recommending, described treatment active ingredient also can adopt following mode to make:
A, get the Herba Houttuyniae of above-mentioned weight proportion, prepare Herba Houttuyniae volatile oil with volatile oil extraction method, medicinal residues are for subsequent use;
B, get the medicinal residues of previous step technique, merge with Herba Sarcandrae, the Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) of above-mentioned weight proportion, water or 30-95% ethanol extraction, filter;
C, refining, concentrated through macroporous resin after concentrated;
D, the Herba Houttuyniae volatile oil of preparing with step a merge, dry, active ingredient obtains medical treatment.
In the embodiment of recommending, described treatment active ingredient is made by the component that comprises following weight proportion: 1～2 part of 1～3 part of Herba Sarcandrae, 1～2 part of Herba Houttuyniae and Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.).
In the embodiment of recommending, described macroporous resin model can be selected from least one in D101, HPD-600, HPD-826, AB-8, HPD-400 or HPD722.
In the embodiment recommending, described Chinese medicine composition is oral formulations.
In the embodiment recommending, described oral formulations is tablet, pill, sublimed preparation, powder, granule, powder, capsule, buccal tablet or effervescent tablet.
In the embodiment recommending, described carrier includes but not limited to filler, disintegrating agent, binding agent, wetting agent, lubricant, and described filler is starch, dextrin, lactose, sucrose, Icing Sugar, microcrystalline Cellulose, glucose, meglumine, glucosamine, mannitol, calcium sulfate or calcium bisulfate; Disintegrating agent is hyprolose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose or crosslinked hydroxypropyl methylcellulose; Binding agent is hydroxypropyl methylcellulose sodium or polyvidone; Wetting agent is water or ethanol; Lubricant is magnesium stearate or Pulvis Talci.
In addition, applicant also finds under study for action, and above-mentioned Chinese medicine composition has the purposes in infectious disease medicament and/or the antibiotic adjuvant drug of, moderate light for the preparation for the treatment of.
In the embodiment recommending, described infectious disease light, moderate is pharyngitis, tonsillitis, sinusitis, otitis media, periodontitis, acute bronchitis, acute episode of chronic bronchitis, pneumonia, skin soft-tissue infection, pure urinary tract infection (cystitis) and complexity urinary tract infection, acute pyelonephritis and rectum infection etc.
Unless specialized, all technology of using here and the implication of scientific terminology are identical with common the understood implication of the technical field of the invention those skilled in the art.Equally, all publications referred in this, patent application, patent and other reference materials are all introduced the present invention as a reference.
The pharmacological evaluation models such as that the present invention adopts is antibacterial in In Vitro Bacteriostasis, body, antiinflammatory, antipyretic, analgesia, find that above medicine uses separately or with Antibiotic combination medication, there is antibacterial, antiinflammatory, antipyretic, analgesic effect, can be used for the treatment of clinically infectious disease light, moderate, replace or reduce antibiotic use, and reducing the use of the medicine of relieve the pain spasmolytic and cooling.
Brief description of the drawings
Fig. 1 is the antipyretic result of the test figure of rat.
Detailed description of the invention
Embodiment 1
Herba Sarcandrae 100g, Herba Houttuyniae 500g, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 100g, adds 70% alcohol reflux 2 times of 8 times of medical material weight, each 1.5h.Merge extractive liquid,, reclaims ethanol, is condensed into relative density 1.25-1.30(60 DEG C of heat and surveys) clear paste, make 82g treatment effective ingredient after dry.
Herba Sarcandrae 500g, Herba Houttuyniae 100g, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 500g, adds 50% alcohol reflux 3 times of 10 times of medical material weight, each 1h.Merge extractive liquid,, reclaim ethanol, be condensed into relative density 1.05-1.15(60 DEG C of heat and survey) clear paste, concentrated solution is added in D101 macroporous resin column after pretreatment, absorption, carry out after eluting with the water of 2 times of column volumes, then use 3 times of column volume 70% ethanol elutions, collect this ethanol elution part, decompression recycling ethanol, and being condensed into fluid extract, spraying is dry, prepares treatment effective ingredient 68g.
Embodiment 3
Get Herba Sarcandrae 300g, Herba Houttuyniae 200g, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 200g, adds 12 times of water gaging reflux, extract, 3 times, each 2h.Merge extractive liquid,, reduces pressure into relative density 1.05-1.15(60 DEG C of heat and surveys) clear paste, be added in AB-8 macroporous resin column after pretreatment absorption; Carry out after eluting with the water of 3 times of column volumes; Use 4 times of column volume 50% ethanol elutions again, collect this ethanol elution part, reclaim ethanol, and be condensed into clear paste, spraying is dry, prepares effective ingredient 41g.
Get Herba Houttuyniae 200g, put in volatile oil extractor, collect volatile oil, for subsequent use.Herba Houttuyniae medicinal residues, add Herba Sarcandrae 200g, and Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 100g adds 12 times of water gagings (6L) reflux, extract, 3 times, each 2h.Merge extractive liquid,, concentrating under reduced pressure becomes 1.05-1.15(60 DEG C of heat to survey) clear paste, be added in HPD-600 macroporous resin column after pretreatment absorption; Carry out after eluting with the water of 3 times of column volumes; Use again 50% ethanol elution of 4 times of column volumes, collect this ethanol elution part, reclaim ethanol, and be condensed into clear paste, be spray dried to dry powder, add volatile oil, dry, prepare effective ingredient 35g.
Embodiment 5
Get Herba Houttuyniae 100g, put in volatile oil extractor, collect volatile oil, with beta-cyclodextrin inclusion compound, for subsequent use.Herba Houttuyniae medicinal residues, add Herba Sarcandrae 100g, and Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) 100g adds 12 times of water gagings (6L) reflux, extract, 3 times, each 2h.Merge extractive liquid,, concentrating under reduced pressure becomes 1.05-1.15(60 DEG C of heat to survey) clear paste, be added in HPD-600 macroporous resin column after pretreatment absorption; Carry out after eluting with the water of 3 times of column volumes; Use again 50% ethanol elution of 4 times of column volumes, collect this ethanol elution part, reclaim ethanol, and be condensed into clear paste, be spray dried to dry powder, add above-mentioned volatile oil clathrate compound, granulate, dry, capsule charge.
Experimental animal pharmacodynamics provided by the invention, clinical practice result and acute toxicity test concrete grammar step are as follows:
Test example 1: the extracorporeal bacteria inhibitor test of medicine of the present invention
The extract that sample: embodiment 1 prepares
Method: get the complete pastille flat board of preparation, every plate is with marking pen labelling and divide 3 of deciles into, and liquid-transfering gun accurately drips 20 μ l bacteria suspensions, all adds bacteria suspension by aforesaid operations on 1/5,1/10,1/20,1/40 pastille flat board.Preparing completely has bacterium pastille flat board to put into constant incubator to cultivate 12h, observed and recorded escherichia coli, staphylococcus aureus, 3 kinds of bacterium of bacillus pyocyaneus are at the dull and stereotyped growing state of 1/5,1/10,1/20,1/40 pastille, minimal inhibitory concentration (MIC): hatch under specific environment 24 hours, can suppress certain microorganism and occur that the lowest concentration of drug rising appreciably is minimal inhibitory concentration, for quantitative assay antibacterial activity in vitro.After 12h, observe the dull and stereotyped escherichia coli of each pastille, staphylococcus aureus, bacillus pyocyaneus growing state, draw three careless extract In Vitro Bacteriostasis minimum inhibitory concentration MIC.
Result: as shown in table 1
Table 1 extracorporeal bacteria inhibitor test
Note: "+" represents to have bacterial clump normal growth, and "-" represents not exist bacterial clump normal growth
The extract that conclusion: embodiment 1 prepares has bacteriostasis: to the MIC=0.003g/ml of staphylococcus aureus; To the MIC=0.005g/ml of bacillus pyocyaneus; To colibacillary MIC=0.01g/ml.
Test example 2: bacteriostatic test in the body of medicine of the present invention
The extract that sample: embodiment 2 prepares
Method: get 50 male and female half and half of body weight 18～22g healthy mice, weigh, number, divide equally at random 5 groups.Blank group is to equal-volume distilled water, positive controls Amoxicillin Capsules 0.6g/kg, extract 7g crude drug/kg for low dose group, extract 14g crude drug/kg for middle dosage group, extract 28g crude drug/kg for high dose group.Each group every morning gastric infusion 1 time, successive administration 3d, 3d administration finishes rear 60min, every mouse peritoneal injection MLD amount (minimum lethal dose) staphylococcus aureus bacteria suspension 0.5ml makes it infect (table 2), continue administration 2d and observe every group of mice 48h activity and death condition timely record, the experiment of bacillus pyocyaneus bacteria suspension group and group technology are with staphylococcus aureus group.
The determination experiment (n=8) of two kinds of bacterium liquid of table 2 to mice MLD
Staphylococcus aureus MLD bacteria suspension concentration is that 4 Maxwell opacity tube concentration are also 10
10cFU/ML(5 bacterium liquid); Bacillus pyocyaneus MLD bacteria suspension concentration is that 1 Maxwell opacity tube concentration is also 10
8cFU/ML(2 bacterium liquid).
Result: as shown in table 3
Bacteriostatic test result in table 3 body
The basic, normal, high dosage of extract that conclusion: embodiment 2 prepares all has the staphylococcus aureus of inhibition, the infection effect of bacillus pyocyaneus to mice, each group all has significant compared with blank group, staphylococcus aureus inhibition is better than to bacillus pyocyaneus, has a certain amount of effect relationship.
Test example 3: antibacterial synergism test is share in medicine of the present invention and amoxicillin
The extract that sample: embodiment 3 prepares
Method: get 50 male and female half and half of body weight 18～22g healthy mice, weigh, number, be divided at random respectively 5 groups, 10 every group.Blank group is to equal-volume distilled water, amoxicillin group 0.6g/kg for positive controls, amoxicillin (0.3g/kg)+low dose group (3.5g crude drug/kg) for associating low dose group, amoxicillin (0.3g/kg)+middle dosage group (7g crude drug/kg) for dosage group in associating, associating is amoxicillin (0.3g/kg)+high dose group (14g crude drug/kg) for high dose group.Each group every morning gastric infusion 1 time, successive administration 3d, 3d administration finishes rear 60min, every mouse peritoneal injection MLD amount staphylococcus aureus bacteria suspension 0.5ml makes its infection, continue administration 2d and observe every group of mice 48h activity and death condition timely record, the experiment of bacillus pyocyaneus bacteria suspension group and group technology are with staphylococcus aureus group.
Result: as shown in table 4
Table 4 is combined bacteriostatic test (n=10) in the body of amoxicillin
The extract associating amoxicillin that conclusion: embodiment 3 prepares has the inhibition of enhancing staphylococcus aureus, the infection effect of bacillus pyocyaneus in Mice Body, each group all has significant, staphylococcus aureus inhibition is better than to bacillus pyocyaneus compared with blank group.
Test example 4: medicine xylol of the present invention causes the impact of mice auricle swelling
The extract that sample: embodiment 4 prepares
Method: 50 healthy KM mices, male and female half and half, weigh, number, and are divided at random respectively 5 groups, 10 every group.Blank group gavage gives equal-volume distilled water, positive controls gavage is to aspirin 0.02g/kg, low dose group gavage gives extract 7g crude drug/kg, middle dosage group gavage gives extract 14g crude drug/kg, and high agent group gavage gives extract 28g crude drug/kg.Each group every morning administration 1 time, successive administration 3d.Last administration finishes rear about 30min, evenly embrocates dimethylbenzene with cotton balls on mouse right ear auricle two sides, and every 0.1ml causes inflammation, and left ear is not coated with and compares.After 1h, the dislocation of mice cervical region is put to death, cut ears, lay round auricle with the card punch of diameter 8mm at the same position of left and right ear, weigh, ask the difference of left and right ear weight as swelling, calculate swelling inhibition percentage and compare group difference.Experimental data all with
represent, between group, data detection adopts the t inspection of two samples, has statistical significance taking P<0.05 as difference.
Result: as shown in table 5
The careless flavone extract of table 5 three affects mouse dimethylbenzene ear expanding
T inspection: compared with blank group
△p<0.05 has significant difference
Mice ear due to the extract xylol that conclusion: embodiment 4 prepares has obvious inhibitory action, and has certain dose-dependence.
Test example 5: medicine of the present invention causes the impact of mice toes swelling on Ovum Gallus domesticus album
The extract that sample: embodiment 4 prepares
Method: get 50 of body weight 18～22g mices, male and female half and half, weigh, number, and are divided at random respectively 5 groups, 10 every group.Blank group gavage gives equal-volume distilled water, positive controls gavage is to aspirin 0.02g/kg, low dose group gavage gives extract 7g crude drug/kg, middle dosage group gavage gives extract 14g crude drug/kg, and high agent group gavage gives extract 28g crude drug/kg.Each group every morning administration 1 time, successive administration 3d.Last administration finishes rear about 30min, and every mice is not injected and compares from the left foot of right back toes aponeurosis (aponeuroses) hemostasis Ovum Gallus domesticus album (from hind leg vola mind-set ankle joint direction inserting needle, subcutaneous administration).After 1h, the dislocation of mice cervical region is put to death, cut biped, with two groups of same mice left and right of tape measuring equal length mice metapedes place clip, weigh, ask the difference of left and right heavy sensation in the foot amount as swelling, calculating swelling inhibition percentage relatively group difference.Experimental data adopts the t inspection of two samples, has statistical significance taking P<0.05 as difference.
Result: as shown in table 6
Table 6 affects the swelling of mice toes
T inspection: compared with blank group
△p<0.05 has significant difference
The extract that conclusion: embodiment 4 prepares causes the swelling of mice toes to Ovum Gallus domesticus album and has obvious inhibitory action, and has certain dose-dependence.
Test example 6: the impact of medicine mice capillary permeability of the present invention
The extract that sample: embodiment 4 prepares
Method: 50 of mices, male and female half and half, weigh, number, and are divided at random respectively 5 groups, 10 every group.Blank group gavage is to equal-volume distilled water, and positive controls is to aspirin 0.02g/kg, and low dose group is to extract 7g crude drug/kg, middle dosage group to extract 14g crude drug/kg, and high agent group is to extract 28g crude drug/kg.Each group every morning gastric infusion 1 time, successive administration 3d.Last administration finishes rear about 45min, tail vein injection 0.5% azovan blue normal saline 0.1ml/10g, and while lumbar injection 0.6% acetum 0.1ml/10g, after 20min, mice is put to death in cervical vertebra dislocation, with 6ml normal saline flushing abdominal cavity, the centrifugal 5min of washing liquid (1500r/min), gets supernatant at spectrophotometer 590nm place, measures A value.T inspection, has statistical significance taking P<0.05 as difference.
Result: as shown in table 7
The experiment of table 7 capillary permeability
T inspection: compared with blank group
△p<0.05
The extract that conclusion: embodiment 4 prepares has effect to mice capillary permeability, and has certain dose-dependence.
Test example 7: the rat solution heat test of medicine of the present invention
The extract that sample: embodiment 4 prepares
Method: select 60 of body temperature SD rats, body weight 150g left and right, male.Test first 3 days, survey body temperature every day 1 time, continuous 3 times, the basal body temperature using meansigma methods as rat.Choose body temperature and change and be no more than 0.3 DEG C and be divided at random 6 groups, be respectively blank group, positive controls (aspirin group) 0.02g/kg, high dose group 28g crude drug/kg, middle dosage group 14g crude drug/kg, low dose group 7g crude drug/kg, 10 every group.Each treated animal is all by the continuous gastric infusion 3d of 1ml/100g above, and once a day, after last administration, each Mus is injected 20% dry yeast suspension in subcutaneous by 10ml/kg immediately, then respectively surveys rat temperature once in 0.5h, 1h, 2h, 4h, 5h, 6h, 7h and 8h.The results are shown in following table 8 and Fig. 1.Between each group, relatively, adopt t inspection.
Result: as shown in table 8, Fig. 1
The impact of table 8 medicine of the present invention on rat pyrogenicity reaction due to dry yeast
T inspection: compared with blank group
△p<0.05,
△ △p<0.01.
The extract that conclusion: embodiment 4 prepares has good refrigeration function, and has certain dose-dependence.
Test example 8: the acetic acid twisting test of medicine of the present invention
The extract that sample: embodiment 4 prepares
Method: 50 of Kunming mouses, body weight 18～22g, male and female half and half, are divided into 5 groups at random, be respectively high dose group 28g crude drug/kg, middle dosage group 14g crude drug/kg, low dose group 7g crude drug/kg, positive controls (aspirin group) 0.02g/kg and normal group, 10 every group.The continuous gastric infusion 3d of each group mice, after last administration 1h, the equal lumbar injection 0.5% acetic acid 0.2ml/ of each Mus only.Each group mouse writhing reaction times in 10min after recording the pain threshold that each group of mice start writhing and starting writhing, and calculate writhing suppression ratio.
Result: as shown in table 9
The impact of table 9 medicine Dichlorodiphenyl Acetate of the present invention induced mice writhing response
T inspection: △ P<0.05 compared with blank group, △ △ P<0.01.
The extract that conclusion: embodiment 4 prepares has good analgesic activity, and has certain dose-dependence.
In sum, the present invention shows by lot of experiments research, and the Chinese herbal medicine formula being made up of Herba Sarcandrae, Herba Houttuyniae, Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) in vitro, in bacteriostatic experiment, all show good bacteriostasis in body, share with amoxicillin, has antibacterial potentiation; Meanwhile, this formula can suppress mice auricle swelling due to dimethylbenzene, it is also inhibited that Ovum Gallus domesticus album is caused to the swelling of mice toes, can reduce mice capillary permeability, points out it to have good antiinflammatory action; This medicine also raises and has good refrigeration function the rat temperature due to dry yeast; In acetic acid twisting test, show good analgesic activity.Above Chinese herbal medicine formula is evident in efficacy, and safety range is large, and technique is simple, and integrated cost is low, is a kind ofly to can be used for prevention and treatment is light, the active drug of grade and moderate infection disease, and can be used as antibiotic adjuvant drug and Antibiotic combination medication.
Above-described embodiment is preferably embodiment of the present invention; but embodiments of the present invention are not restricted to the described embodiments; other any do not deviate from change, the modification done under spirit of the present invention and principle, substitutes, combination, simplify; all should be equivalent substitute mode, within being included in protection scope of the present invention.
Claims (9)
1. the analgesia Chinese medicine composition of bringing down a fever, comprises treatment active ingredient and the carrier that pharmaceutically can use, it is characterized in that, described treatment active ingredient is made by the component of following weight proportion: 1～5 part of 1～5 part of Herba Sarcandrae, 1～5 part of Herba Houttuyniae and Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.).
2. according to the analgesia Chinese medicine composition of bringing down a fever of the one described in claim 1, it is characterized in that, described treatment active ingredient is used following mode to make:
A, the Herba Houttuyniae of getting described weight proportion, Herba Sarcandrae and Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.), water or 30-95% ethanol extraction, filter;
B, be directly concentrated into clear paste;
C, dry directly make.
3. according to the analgesia Chinese medicine composition of bringing down a fever of the one described in claim 1, it is characterized in that, described treatment active ingredient is used following mode to make:
A, get the Herba Houttuyniae of described weight proportion, prepare Herba Houttuyniae volatile oil with volatile oil extraction method, medicinal residues are for subsequent use;
B, get the medicinal residues of previous step technique, merge with Herba Sarcandrae, the Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.) of described weight proportion, water or 30-95% ethanol extraction, filter;
C, refining, concentrated through macroporous resin after concentrated;
D, the Herba Houttuyniae volatile oil of preparing with step a merge, dry, active ingredient obtains medical treatment.
4. according to the analgesia Chinese medicine composition of bringing down a fever of the one described in claim 1, it is characterized in that, described treatment active ingredient is made by the component that comprises following weight proportion: 1～2 part of 1～3 part of Herba Sarcandrae, 1～2 part of Herba Houttuyniae and Herba ajugae ciliatae (Herba Ajugae Ajuga ciliata Bge.).
5. according to the analgesia Chinese medicine composition of bringing down a fever of the one described in claim 3, it is characterized in that: described macroporous resin model is selected from least one in D101, HPD-600, HPD-826, AB-8, HPD-400 or HPD722.
6. according to the analgesia Chinese medicine composition of bringing down a fever of the one described in claim 1, it is characterized in that: described Chinese medicine composition is oral formulations.
7. according to the analgesia Chinese medicine composition of bringing down a fever of the one described in claim 6, it is characterized in that: described oral formulations is tablet, pill, sublimed preparation, powder, granule, powder, capsule, buccal tablet or effervescent tablet.
8. according to the analgesia Chinese medicine composition of bringing down a fever of the one described in claim 1, it is characterized in that: described carrier includes but not limited to filler, disintegrating agent, binding agent, wetting agent, lubricant, described filler is starch, dextrin, lactose, sucrose, Icing Sugar, microcrystalline Cellulose, glucose, meglumine, glucosamine, mannitol, calcium sulfate or calcium bisulfate; Disintegrating agent is hyprolose, carboxymethyl starch sodium, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose or crosslinked hydroxypropyl methylcellulose; Binding agent is hydroxypropyl methylcellulose sodium or polyvidone; Wetting agent is water or ethanol; Lubricant is magnesium stearate or Pulvis Talci.
9. the purposes of analgesia Chinese medicine composition in, grade and moderate infection disease medicament light for the preparation for the treatment of and/or antibiotic adjuvant drug of bringing down a fever of claim 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410150098.9A CN103893353A (en) | 2014-04-15 | 2014-04-15 | Traditional Chinese medicinal composition for bringing down fever and relieving pain and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410150098.9A CN103893353A (en) | 2014-04-15 | 2014-04-15 | Traditional Chinese medicinal composition for bringing down fever and relieving pain and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103893353A true CN103893353A (en) | 2014-07-02 |
Family
ID=50985137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410150098.9A Pending CN103893353A (en) | 2014-04-15 | 2014-04-15 | Traditional Chinese medicinal composition for bringing down fever and relieving pain and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893353A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906240A (en) * | 2015-06-08 | 2015-09-16 | 吉林大学珠海学院 | Anti-inflammation and analgesic compound purslane Chinese herba preparation and preparing method thereof |
| CN116211993A (en) * | 2023-03-29 | 2023-06-06 | 天等县人民医院 | Composition for treating senile chronic disease and its preparation method |
-
2014
- 2014-04-15 CN CN201410150098.9A patent/CN103893353A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 李丽珍: "三草素的药效学和急性毒性研究", 《中国优秀硕士学位论文全文数据库》 * |
| 李丽珍: "三草素的药效学和急性毒性研究", 《中国优秀硕士学位论文全文数据库》, 8 July 2013 (2013-07-08) * |
| 李富艳: "正交设计优选三草素胶囊总黄酮提取的最佳工艺", 《福建中医药大学学报》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906240A (en) * | 2015-06-08 | 2015-09-16 | 吉林大学珠海学院 | Anti-inflammation and analgesic compound purslane Chinese herba preparation and preparing method thereof |
| CN104906240B (en) * | 2015-06-08 | 2018-08-28 | 吉林大学珠海学院 | A kind of compound purslane Chinese medicine preparation of easing pain and diminishing inflammation and preparation method thereof |
| CN116211993A (en) * | 2023-03-29 | 2023-06-06 | 天等县人民医院 | Composition for treating senile chronic disease and its preparation method |
| CN116211993B (en) * | 2023-03-29 | 2024-03-26 | 天等县人民医院 | Composition for treating senile chronic disease and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101700307B (en) | Traditional Chinese medicine for curing chronic pharyngolaryngitis | |
| CN104367765A (en) | Traditional Chinese medicinal composition for treating depression as well as preparation method and application thereof | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN1806821A (en) | Rhinitis-treating medicine | |
| CN101703572B (en) | Method for preparing Chinese medicinal composition for treating respiratory disease of livestock and application thereof | |
| CN103405494B (en) | Bauhinia championii n-butyl alcohol extract and preparation method and application thereof | |
| CN103893353A (en) | Traditional Chinese medicinal composition for bringing down fever and relieving pain and application thereof | |
| CN1292779C (en) | Chinese traditional medicine preparation for treating paediatric acute tonsillitis | |
| CN1943729A (en) | A Chinese traditional medicinal composition for treatment of exopathic febrile disease and its preparation method | |
| CN103191175A (en) | Diarrhoea-stopping traditional Chinese medicine composition, capsule and application thereof | |
| CN1460513A (en) | Jinlian Qingre capsule and its preparation method | |
| CN1278709C (en) | Medicine for treating cold and its preparing process | |
| CN104116821A (en) | Anti-inflammatory and analgesic medicine composition and application thereof | |
| CN103638353B (en) | One treats phthisical Chinese medicine composition | |
| CN105031025B (en) | Compound Chinese medicinal preparation for treating porcine mycoplasmal pneumonia and preparation method thereof | |
| CN101607009B (en) | Pharmaceutical composition for treating cold | |
| CN103933376B (en) | Medicinal composition for treating chronic bronchitis | |
| CN100333744C (en) | Acne treating medicine | |
| CN101926846A (en) | Medicinal composition for treating pullorum disease and preparation method thereof | |
| CN1500505A (en) | Medication composition for children 's virus pneumonia and its preparation method | |
| CN100394967C (en) | Chinese medicine composition for treating wrinary tract disease | |
| CN101642495A (en) | Method for producing traditional Chinese medicine preparation with functions of protecting liver, lowering enzymes and enhancing immunity | |
| CN101569714A (en) | Traditional Chinese medicine compound for treating chronic pharyngitis and the preparation method thereof | |
| CN103536784A (en) | Traditional Chinese medicine for treating laryngitis as well as preparation method thereof | |
| CN1403129A (en) | Chinese medicine prepn for stopping drug addiction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140702 |